Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/09/12 07:56:23」(JST)

wiki en

A cannabinoid is one of a class of diverse chemical compounds that acts on cannabinoid receptors in cells that alter neurotransmitter release in the brain. Ligands for these receptor proteins include the endocannabinoids (produced naturally in the body by animals),^[1] the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (manufactured artificially). The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis.^[2]^[3] Cannabidiol (CBD) is another major constituent of the plant.^[4] There are at least 113 different cannabinoids isolated from cannabis, exhibiting varied effects.^[5]

Synthetic cannabinoids encompass a variety of distinct chemical classes: the classical cannabinoids structurally related to THC, the nonclassical cannabinoids (cannabimimetics) including the aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, and arylsulfonamides as well as eicosanoids related to endocannabinoids.^[2]

1 Cannabinoid receptors
- 1.1 Cannabinoid receptor type 1
- 1.2 Cannabinoid receptor type 2
2 Phytocannabinoids
- 2.1 Cannabis-derived cannabinoids
  - 2.1.1 Types
    - 2.1.1.1 Tetrahydrocannabinol
    - 2.1.1.2 Cannabidiol
    - 2.1.1.3 Cannabinol
    - 2.1.1.4 Cannabigerol
    - 2.1.1.5 Tetrahydrocannabivarin
    - 2.1.1.6 Cannabidivarin
    - 2.1.1.7 Cannabichromene
    - 2.1.1.8 Biosynthesis
    - 2.1.1.9 Double bond position
    - 2.1.1.10 Length
- 2.2 Cannabinoids in other plants
- 2.3 Cannabis plant profile
- 2.4 Pharmacology
- 2.5 Separation
- 2.6 History
3 Endocannabinoids
- 3.1 Types of endocannabinoid ligands
  - 3.1.1 Arachidonoylethanolamine (Anandamide or AEA)
  - 3.1.2 2-Arachidonoylglycerol (2-AG)
  - 3.1.3 2-Arachidonyl glyceryl ether (noladin ether)
  - 3.1.4 N-Arachidonoyl dopamine (NADA)
  - 3.1.5 Virodhamine (OAE)
  - 3.1.6 Lysophosphatidylinositol (LPI)
- 3.2 Function
  - 3.2.1 Retrograde signal
  - 3.2.2 Range
4 Synthetic cannabinoids
5 Table of plant cannabinoids
6 See also
7 References

Cannabinoid receptors

Before the 1980s, it was often speculated that cannabinoids produced their physiological and behavioral effects via nonspecific interaction with cell membranes, instead of interacting with specific membrane-bound receptors. The discovery of the first cannabinoid receptors in the 1980s helped to resolve this debate.^[6] These receptors are common in animals, and have been found in mammals, birds, fish, and reptiles. At present, there are two known types of cannabinoid receptors, termed CB₁ and CB₂,^[1] with mounting evidence of more.^[7] The human brain has more cannabinoid receptors than any other G protein-coupled receptor (GPCR) type.^[8]

Cannabinoid receptor type 1

CB₁ receptors are found primarily in the brain, more specifically in the basal ganglia and in the limbic system, including the hippocampus ^[1] and the striatum. They are also found in the cerebellum and in both male and female reproductive systems. CB₁ receptors are absent in the medulla oblongata, the part of the brain stem responsible for respiratory and cardiovascular functions. CB1 is also found in the human anterior eye and retina.^[9]

Cannabinoid receptor type 2

CB₂ receptors are predominantly found in the immune system, or immune-derived cells^[10] with the greatest density in the spleen. While found only in the peripheral nervous system, a report does indicate that CB₂ is expressed by a subpopulation of microglia in the human cerebellum.^[11] CB₂ receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis seen in animal models.^[10]

Phytocannabinoids

Type	Skeleton	Cyclization
Cannabigerol-type CBG
Cannabichromene-type CBC
Cannabidiol-type CBD
Tetrahydrocannabinol- and Cannabinol-type THC, CBN
Cannabielsoin-type CBE
iso- Tetrahydrocannabinol- type iso-THC
Cannabicyclol-type CBL
Cannabicitran-type CBT
Main classes of natural cannabinoids

The bracts surrounding a cluster of Cannabis sativa flowers are coated with cannabinoid-laden trichomes

Cannabis-derived cannabinoids

Cannabis indica plant

The classical cannabinoids are concentrated in a viscous resin produced in structures known as glandular trichomes. At least 113 different cannabinoids have been isolated from the Cannabis plant^[5] To the right, the main classes of cannabinoids from Cannabis are shown. The best studied cannabinoids include tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN).

Types

All classes derive from cannabigerol-type (CBG) compounds and differ mainly in the way this precursor is cyclized.^[12] The classical cannabinoids are derived from their respective 2-carboxylic acids (2-COOH) by decarboxylation (catalyzed by heat, light, or alkaline conditions).^[13]

THC (Tetrahydrocannabinol)
THCA (Tetrahydrocannabinolic acid)
CBD (Cannabidiol)
CBDA (Cannabidiolic Acid)
CBN (Cannabinol)
CBG (Cannabigerol)
CBC (Cannabichromene)
CBL (Cannabicyclol)
CBV (Cannabivarin)
THCV (Tetrahydrocannabivarin)
CBDV (Cannabidivarin)
CBCV (Cannabichromevarin)
CBGV (Cannabigerovarin)
CBGM (Cannabigerol Monomethyl Ether)
CBE (Cannabielsoin)
CBT (Cannabicitran)

Tetrahydrocannabinol

Tetrahydrocannabinol (THC) is the primary psychoactive component of the Cannabis plant. Delta-9-tetrahydrocannabinol (Δ⁹-THC, THC) and delta-8-tetrahydrocannabinol (Δ⁸-THC), through intracellular CB₁ activation, induce anandamide and 2-arachidonoylglycerol synthesis produced naturally in the body and brain. These cannabinoids produce the effects associated with cannabis by binding to the CB₁ cannabinoid receptors in the brain.

Cannabidiol

Cannabidiol (CBD) is non-psychotropic. Recent evidence shows that the compound counteracts cognitive impairment associated with the use of cannabis.^[14] Cannabidiol has little affinity for CB₁ and CB₂ receptors but acts as an indirect antagonist of cannabinoid agonists.^[15] It was found to be an antagonist at the putative new cannabinoid receptor, GPR55, a GPCR expressed in the caudate nucleus and putamen.^[16] Cannabidiol has also been shown to act as a 5-HT_1A receptor agonist.^[17] CBD can interfere with the uptake of adenosine, which plays an important role in biochemical processes, such as energy transfer.^{[citation needed]} It may play a role in promoting sleep and suppressing arousal.^[18]

CBD shares a precursor with THC and is the main cannabinoid in CBD-dominant Cannabis strains. CBD has been shown to play a role in preventing the short-term memory loss associated with THC.^[19]

There is tentative evidence that CBD had an anti-psychotic effect, but research in this area is limited.^[20]^[14]

Cannabinol

Cannabinol (CBN) is the primary product of THC degradation, and there is usually little of it in a fresh plant.^{[citation needed]} CBN content increases as THC degrades in storage, and with exposure to light and air.^{[citation needed]} It is only mildly psychoactive. Its affinity to the CB₂ receptor is higher than for the CB₁ receptor.^[21]

Cannabigerol

Cannabigerol (CBG) is non-psychoactive but still contributes to the overall effects of Cannabis. CBG has been shown to promote apoptosis in cancer cells and inhibit tumor growth in mice.^[22] It acts as an α₂-adrenergic receptor agonist, 5-HT_1A receptor antagonist, and CB₁ receptor antagonist.^[23] It also binds to the CB₂ receptor.^[23]

Tetrahydrocannabivarin

Tetrahydrocannabivarin (THCV) is prevalent in certain central Asian and southern African strains of Cannabis.^[24]^[25] It is an antagonist of THC at CB₁ receptors and attenuates the psychoactive effects of THC.^[26]

Cannabidivarin

Although cannabidivarin (CBDV) is usually a minor constituent of the cannabinoid profile, enhanced levels of CBDV have been reported in feral cannabis plants from the northwest Himalayas, and in hashish from Nepal.^[25]^[27]

Cannabichromene

Cannabichromene (CBC) is non-psychoactive and does not affect the psychoactivity of THC.^[28] CBC has shown antitumor effects in breast cancer xenoplants in mice.^[29] More common in tropical cannabis varieties.

Biosynthesis

Cannabinoid production starts when an enzyme causes geranyl pyrophosphate and olivetolic acid to combine and form CBGA. Next, CBGA is independently converted to either CBG, THCA, CBDA or CBCA by four separate synthase, FAD-dependent dehydrogenase enzymes. There is no evidence for enzymatic conversion of CBDA or CBD to THCA or THC. For the propyl homologues (THCVA, CBDVA and CBCVA), there is an analogous pathway that is based on CBGVA from divarinolic acid instead of olivetolic acid.

Double bond position

In addition, each of the compounds above may be in different forms depending on the position of the double bond in the alicyclic carbon ring. There is potential for confusion because there are different numbering systems used to describe the position of this double bond. Under the dibenzopyran numbering system widely used today, the major form of THC is called Δ⁹-THC, while the minor form is called Δ⁸-THC. Under the alternate terpene numbering system, these same compounds are called Δ¹-THC and Δ⁶-THC, respectively.

Length

Most classical cannabinoids are 21-carbon compounds. However, some do not follow this rule, primarily because of variation in the length of the side-chain attached to the aromatic ring. In THC, CBD, and CBN, this side-chain is a pentyl (5-carbon) chain. In the most common homologue, the pentyl chain is replaced with a propyl (3-carbon) chain. Cannabinoids with the propyl side chain are named using the suffix varin, and are designated, for example, THCV, CBDV, or CBNV.

Cannabinoids in other plants

Phytocannabinoids are known to occur in several plant species besides cannabis. These include Echinacea purpurea, Echinacea angustifolia, Acmella oleracea, Helichrysum umbraculigerum, and Radula marginata.^[30] The best-known cannabinoids that are not derived from Cannabis are the lipophilic alkamides (alkylamides) from Echinacea species, most notably the cis/trans isomers dodeca-2E,4E,8Z,10E/Z-tetraenoic-acid-isobutylamide.^[30] At least 25 different alkylamides have been identified, and some of them have shown affinities to the CB₂-receptor.^[31]^[32] In some Echinacea species, cannabinoids are found throughout the plant structure, but are most concentrated in the roots and flowers.^[33]^[34] Yangonin found in the Kava plant has significant affinity to the CB1 receptor.^[35] Tea (Camellia sinensis) catechins have an affinity for human cannabinoid receptors.^[36] A widespread dietary terpene, beta-caryophyllene, a component from the essential oil of cannabis and other medicinal plants, has also been identified as a selective agonist of peripheral CB₂-receptors, in vivo.^[37] Black truffles contain anandamide.^[38]

Most of the phytocannabinoids are nearly insoluble in water but are soluble in lipids, alcohols, and other non-polar organic solvents.

Cannabis plant profile

Cannabis plants can exhibit wide variation in the quantity and type of cannabinoids they produce. The mixture of cannabinoids produced by a plant is known as the plant's cannabinoid profile. Selective breeding has been used to control the genetics of plants and modify the cannabinoid profile. For example, strains that are used as fiber (commonly called hemp) are bred such that they are low in psychoactive chemicals like THC. Strains used in medicine are often bred for high CBD content, and strains used for recreational purposes are usually bred for high THC content or for a specific chemical balance.

Quantitative analysis of a plant's cannabinoid profile is often determined by gas chromatography (GC), or more reliably by gas chromatography combined with mass spectrometry (GC/MS). Liquid chromatography (LC) techniques are also possible and, unlike GC methods, can differentiate between the acid and neutral forms of the cannabinoids. There have been systematic attempts to monitor the cannabinoid profile of cannabis over time, but their accuracy is impeded by the illegal status of the plant in many countries.

Pharmacology

Cannabinoids can be administered by smoking, vaporizing, oral ingestion, transdermal patch, intravenous injection, sublingual absorption, or rectal suppository. Once in the body, most cannabinoids are metabolized in the liver, especially by cytochrome P450 mixed-function oxidases, mainly CYP 2C9.^[39] Thus supplementing with CYP 2C9 inhibitors leads to extended intoxication.^[39]

Some is also stored in fat in addition to being metabolized in the liver. Δ⁹-THC is metabolized to 11-hydroxy-Δ⁹-THC, which is then metabolized to 9-carboxy-THC.^[40] Some cannabis metabolites can be detected in the body several weeks after administration. These metabolites are the chemicals recognized by common antibody-based "drug tests"; in the case of THC or others, these loads do not represent intoxication (compare to ethanol breath tests that measure instantaneous blood alcohol levels), but an integration of past consumption over an approximately month-long window. This is because they are fat-soluble, lipophilic molecules that accumulate in fatty tissues.^[41]

Separation

Cannabinoids can be separated from the plant by extraction with organic solvents. Hydrocarbons and alcohols are often used as solvents. However, these solvents are flammable and many are toxic. Butane may be used, which evaporates extremely quickly. Supercritical solvent extraction with carbon dioxide is an alternative technique. Once extracted, isolated components can be separated using wiped film vacuum distillation or other distillation techniques.

History

Cannabinoids were first discovered in the 1940s when CBD and CBN were identified. The structure of THC was first determined in 1964.^{[citation needed]}

Due to molecular similarity and ease of synthetic conversion, CBD was originally believed to be a natural precursor to THC. However, it is now known that CBD and THC are produced independently in the cannabis plant from the precursor CBG.^{[citation needed]}

Endocannabinoids

Anandamide, an endogenous ligand of CB₁ and CB₂

Endocannabinoids are substances produced from within the body that activate cannabinoid receptors. After the discovery of the first cannabinoid receptor in 1988, scientists began searching for an endogenous ligand for the receptor.^[6]^[42]

Types of endocannabinoid ligands

Arachidonoylethanolamine (Anandamide or AEA)

Anandamide was the first such compound identified as arachidonoyl ethanolamine. The name is derived from the Sanskrit word for bliss and -amide. It has a pharmacology similar to THC, although its structure is quite different. Anandamide binds to the central (CB₁) and, to a lesser extent, peripheral (CB₂) cannabinoid receptors, where it acts as a partial agonist. Anandamide is about as potent as THC at the CB₁ receptor.^[43] Anandamide is found in nearly all tissues in a wide range of animals.^[44] Anandamide has also been found in plants, including small amounts in chocolate.^[45]

Two analogs of anandamide, 7,10,13,16-docosatetraenoylethanolamide and homo-γ-linolenoylethanolamine, have similar pharmacology. All of these compounds are members of a family of signalling lipids called N-acylethanolamines, which also includes the noncannabimimetic palmitoylethanolamide and oleoylethanolamide, which possess anti-inflammatory and orexigenic effects, respectively. Many N-acylethanolamines have also been identified in plant seeds^[46] and in molluscs.^[47]

2-Arachidonoylglycerol (2-AG)

Another endocannabinoid, 2-arachidonoylglycerol, binds to both the CB₁ and CB₂ receptors with similar affinity, acting as a full agonist at both.^[43] 2-AG is present at significantly higher concentrations in the brain than anandamide,^[48] and there is some controversy over whether 2-AG rather than anandamide is chiefly responsible for endocannabinoid signalling in vivo.^[1] In particular, one in vitro study suggests that 2-AG is capable of stimulating higher G-protein activation than anandamide, although the physiological implications of this finding are not yet known.^[49]

2-Arachidonyl glyceryl ether (noladin ether)

In 2001, a third, ether-type endocannabinoid, 2-arachidonyl glyceryl ether (noladin ether), was isolated from porcine brain.^[50] Prior to this discovery, it had been synthesized as a stable analog of 2-AG; indeed, some controversy remains over its classification as an endocannabinoid, as another group failed to detect the substance at "any appreciable amount" in the brains of several different mammalian species.^[51] It binds to the CB₁ cannabinoid receptor (K_i = 21.2 nmol/L) and causes sedation, hypothermia, intestinal immobility, and mild antinociception in mice. It binds primarily to the CB₁ receptor, and only weakly to the CB₂ receptor.^[43]

N-Arachidonoyl dopamine (NADA)

Discovered in 2000, NADA preferentially binds to the CB₁ receptor.^[52] Like anandamide, NADA is also an agonist for the vanilloid receptor subtype 1 (TRPV1), a member of the vanilloid receptor family.^[53]^[54]

Virodhamine (OAE)

A fifth endocannabinoid, virodhamine, or O-arachidonoyl-ethanolamine (OAE), was discovered in June 2002. Although it is a full agonist at CB₂ and a partial agonist at CB₁, it behaves as a CB₁ antagonist in vivo. In rats, virodhamine was found to be present at comparable or slightly lower concentrations than anandamide in the brain, but 2- to 9-fold higher concentrations peripherally.^[55]

Lysophosphatidylinositol (LPI)

Recent evidence has highlighted lysophosphatidylinositol as the endogenous ligand to novel endocannabinoid receptor GPR55, making it a strong contender as the sixth endocannabinoid.^[56]

Function

Endocannabinoids serve as intercellular 'lipid messengers', signaling molecules that are released from one cell and activating the cannabinoid receptors present on other nearby cells. Although in this intercellular signaling role they are similar to the well-known monoamine neurotransmitters such as dopamine, endocannabinoids differ in numerous ways from them. For instance, they are used in retrograde signaling between neurons. Furthermore, endocannabinoids are lipophilic molecules that are not very soluble in water. They are not stored in vesicles and exist as integral constituents of the membrane bilayers that make up cells. They are believed to be synthesized 'on-demand' rather than made and stored for later use. The mechanisms and enzymes underlying the biosynthesis of endocannabinoids remain elusive and continue to be an area of active research.

The endocannabinoid 2-AG has been found in bovine and human maternal milk.^[57]

Retrograde signal

Conventional neurotransmitters are released from a ‘presynaptic’ cell and activate appropriate receptors on a ‘postsynaptic’ cell, where presynaptic and postsynaptic designate the sending and receiving sides of a synapse, respectively. Endocannabinoids, on the other hand, are described as retrograde transmitters because they most commonly travel ‘backward’ against the usual synaptic transmitter flow. They are, in effect, released from the postsynaptic cell and act on the presynaptic cell, where the target receptors are densely concentrated on axonal terminals in the zones from which conventional neurotransmitters are released. Activation of cannabinoid receptors temporarily reduces the amount of conventional neurotransmitter released. This endocannabinoid-mediated system permits the postsynaptic cell to control its own incoming synaptic traffic. The ultimate effect on the endocannabinoid-releasing cell depends on the nature of the conventional transmitter being controlled. For instance, when the release of the inhibitory transmitter GABA is reduced, the net effect is an increase in the excitability of the endocannabinoid-releasing cell. On the converse, when release of the excitatory neurotransmitter glutamate is reduced, the net effect is a decrease in the excitability of the endocannabinoid-releasing cell.^{[citation needed]}

Range

Endocannabinoids are hydrophobic molecules. They cannot travel unaided for long distances in the aqueous medium surrounding the cells from which they are released and therefore act locally on nearby target cells. Hence, although emanating diffusely from their source cells, they have much more restricted spheres of influence than do hormones, which can affect cells throughout the body.^{[citation needed]}

Synthetic cannabinoids

Historically, laboratory synthesis of cannabinoids were often based on the structure of herbal cannabinoids, and a large number of analogs have been produced and tested, especially in a group led by Roger Adams as early as 1941 and later in a group led by Raphael Mechoulam. Newer compounds are no longer related to natural cannabinoids or are based on the structure of the endogenous cannabinoids.^[58]

Synthetic cannabinoids are particularly useful in experiments to determine the relationship between the structure and activity of cannabinoid compounds, by making systematic, incremental modifications of cannabinoid molecules.^[59]

When synthetic cannabinoids are used recreationally, they present significant health dangers to users.^[60] In the period of 2012 through 2014, over 10,000 contacts to poison control centers in the United States were related to use of synthetic cannabinoids.^[60]

Medications containing natural or synthetic cannabinoids or cannabinoid analogs:

Dronabinol (Marinol), is Δ⁹-tetrahydrocannabinol (THC), used as an appetite stimulant, anti-emetic, and analgesic
Nabilone (Cesamet, Canemes), a synthetic cannabinoid and an analog of Marinol. It is Schedule II unlike Marinol, which is Schedule III
Rimonabant (SR141716), a selective cannabinoid (CB₁) receptor inverse agonist once used as an anti-obesity drug under the proprietary name Acomplia. It was also used for smoking cessation

Other notable synthetic cannabinoids include:

JWH-018, a potent synthetic cannabinoid agonist discovered by John W. Huffman at Clemson University. It is being increasingly sold in legal smoke blends collectively known as "spice". Several countries and states have moved to ban it legally.
JWH-073
CP-55940, produced in 1974, this synthetic cannabinoid receptor agonist is many times more potent than THC.
Dimethylheptylpyran
HU-210, about 100 times as potent as THC^[61]
HU-331 a potential anti-cancer drug derived from cannabidiol that specifically inhibits topoisomerase II.
SR144528, a CB₂ receptor antagonist
WIN 55,212-2, a potent cannabinoid receptor agonist
JWH-133, a potent selective CB₂ receptor agonist
Levonantradol (Nantrodolum), an anti-emetic and analgesic but not currently in use in medicine
AM-2201, a potent cannabinoid receptor agonist

Table of plant cannabinoids

Table of plant cannabinoids
Cannabigerol-type (CBG)
Cannabigerol (E)-CBG-C₅	Cannabigerol monomethyl ether (E)-CBGM-C₅ A	Cannabinerolic acid A (Z)-CBGA-C₅ A	Cannabigerovarin (E)-CBGV-C₃
Cannabigerolic acid A (E)-CBGA-C₅ A	Cannabigerolic acid A monomethyl ether (E)-CBGAM-C₅ A		Cannabigerovarinic acid A (E)-CBGVA-C₃ A
Cannabichromene-type (CBC)
(±)-Cannabichromene CBC-C₅	(±)-Cannabichromenic acid A CBCA-C₅ A	(±)-Cannabivarichromene, (±)-Cannabichromevarin CBCV-C₃	(±)-Cannabichromevarinic acid A CBCVA-C₃ A
Cannabidiol-type (CBD)
(−)-Cannabidiol CBD-C₅	Cannabidiol momomethyl ether CBDM-C₅	Cannabidiol-C₄ CBD-C₄	(−)-Cannabidivarin CBDV-C₃	Cannabidiorcol CBD-C₁
Cannabidiolic acid CBDA-C₅			Cannabidivarinic acid CBDVA-C₃
Cannabinodiol-type (CBND)
Cannabinodiol CBND-C₅	Cannabinodivarin CBND-C₃
Tetrahydrocannabinol-type (THC)
Δ⁹-Tetrahydrocannabinol Δ⁹-THC-C₅		Δ⁹-Tetrahydrocannabinol-C₄ Δ⁹-THC-C₄	Δ⁹-Tetrahydrocannabivarin Δ⁹-THCV-C₃	Δ⁹-Tetrahydrocannabiorcol Δ⁹-THCO-C₁
Δ⁹-Tetrahydro- cannabinolic acid A Δ⁹-THCA-C₅ A	Δ⁹-Tetrahydro- cannabinolic acid B Δ⁹-THCA-C₅ B	Δ⁹-Tetrahydro- cannabinolic acid-C₄ A and/or B Δ⁹-THCA-C₄ A and/or B	Δ⁹-Tetrahydro- cannabivarinic acid A Δ⁹-THCVA-C₃ A	Δ⁹-Tetrahydro- cannabiorcolic acid A and/or B Δ⁹-THCOA-C₁ A and/or B
(−)-Δ⁸-trans-(6aR,10aR)- Δ⁸-Tetrahydrocannabinol Δ⁸-THC-C₅	(−)-Δ⁸-trans-(6aR,10aR)- Tetrahydrocannabinolic acid A Δ⁸-THCA-C₅ A	(−)-(6aS,10aR)-Δ⁹- Tetrahydrocannabinol *(−)-cis-Δ⁹-THC-C₅*
Cannabinol-type (CBN)
Cannabinol CBN-C₅	Cannabinol-C₄ CBN-C₄	Cannabivarin CBN-C₃	Cannabinol-C₂ CBN-C₂	Cannabiorcol CBN-C₁
Cannabinolic acid A CBNA-C₅ A	Cannabinol methyl ether CBNM-C₅
Cannabitriol-type (CBT)
(−)-(9R,10R)-trans- Cannabitriol *(−)-trans-CBT-C₅*	(+)-(9S,10S)-Cannabitriol *(+)-trans-CBT-C₅*	(±)-(9R,10S/9S,10R)- Cannabitriol *(±)-cis-CBT-C₅*	(−)-(9R,10R)-trans- 10-O-Ethyl-cannabitriol *(−)-trans-CBT-OEt-C₅*	(±)-(9R,10R/9S,10S)- Cannabitriol-C₃ *(±)-trans-CBT-C₃*
8,9-Dihydroxy-Δ^6a(10a)- tetrahydrocannabinol 8,9-Di-OH-CBT-C₅	Cannabidiolic acid A cannabitriol ester CBDA-C₅ 9-OH-CBT-C₅ ester	(−)-(6aR,9S,10S,10aR)- 9,10-Dihydroxy- hexahydrocannabinol, Cannabiripsol Cannabiripsol-C₅	(−)-6a,7,10a-Trihydroxy- Δ⁹-tetrahydrocannabinol (−)-Cannabitetrol	10-Oxo-Δ^6a(10a)- tetrahydrocannabinol OTHC
Cannabielsoin-type (CBE)
(5aS,6S,9R,9aR)- Cannabielsoin CBE-C₅		(5aS,6S,9R,9aR)- C₃-Cannabielsoin CBE-C₃
(5aS,6S,9R,9aR)- Cannabielsoic acid A CBEA-C₅ A	(5aS,6S,9R,9aR)- Cannabielsoic acid B CBEA-C₅ B	(5aS,6S,9R,9aR)- C₃-Cannabielsoic acid B CBEA-C₃ B
Cannabiglendol-C₃ OH-iso-HHCV-C₃	Dehydrocannabifuran DCBF-C₅	Cannabifuran CBF-C₅
Isocannabinoids
(−)-Δ⁷-trans-(1R,3R,6R)- Isotetrahydrocannabinol	(±)-Δ⁷-1,2-cis- (1R,3R,6S/1S,3S,6R)- Isotetrahydro- cannabivarin	(−)-Δ⁷-trans-(1R,3R,6R)- Isotetrahydrocannabivarin
Cannabicyclol-type (CBL)
(±)-(1aS,3aR,8bR,8cR)- Cannabicyclol CBL-C₅	(±)-(1aS,3aR,8bR,8cR)- Cannabicyclolic acid A CBLA-C₅ A	(±)-(1aS,3aR,8bR,8cR)- Cannabicyclovarin CBLV-C₃
Cannabicitran-type (CBT)
Cannabicitran CBT-C₅
Cannabichromanone-type (CBCN)
Cannabichromanone CBCN-C₅	Cannabichromanone-C₃ CBCN-C₃	Cannabicoumaronone CBCON-C₅

References

^ ^a ^b ^c ^d Pacher, P.; Bátkai, S; Kunos, G (2006). "The Endocannabinoid System as an Emerging Target of Pharmacotherapy". Pharmacological Reviews. 58 (3): 389–462. PMC 2241751 . PMID 16968947. doi:10.1124/pr.58.3.2.
^ ^a ^b Lambert, Didier M.; Fowler, Christopher J. (2005). "The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications". Journal of Medicinal Chemistry. 48 (16): 5059–87. PMID 16078824. doi:10.1021/jm058183t.
^ Pertwee, Roger, ed. (2005). Cannabinoids. Springer-Verlag. p. 2. ISBN 3-540-22565-X.
^ "Bulletin on Narcotics – 1962 Issue 3 – 004". UNODC (United Nations Office of Drugs and Crime). 1962-01-01. Retrieved 2014-01-15.
^ ^a ^b Aizpurua-Olaizola, Oier; Soydaner, Umut; Öztürk, Ekin; Schibano, Daniele; Simsir, Yilmaz; Navarro, Patricia; Etxebarria, Nestor; Usobiaga, Aresatz (2016-02-02). "Evolution of the Cannabinoid and Terpene Content during the Growth ofCannabis sativaPlants from Different Chemotypes". Journal of Natural Products. 79 (2): 324–331. PMID 26836472. doi:10.1021/acs.jnatprod.5b00949.
^ ^a ^b Devane, WA; Dysarz, FA 3rd; Johnson, MR; Melvin, LS; Howlett, AC (1988). "Determination and characterization of a cannabinoid receptor in rat brain". Mol Pharmacol. 34 (5): 605–13. PMID 2848184. Retrieved 6 June 2015.
^ Begg, Malcolm; Pacher, Pál; Batkai, Sándor; Oseihyiaman, Douglas; Offertaler, László; Mo, Fong Ming; Liu, Jie; Kunos, George (2005). "Evidence for novel cannabinoid receptors". Pharmacology & Therapeutics. 106 (2): 133–45. PMID 15866316. doi:10.1016/j.pharmthera.2004.11.005.
^ Boron, Walter F.; Boulpaep, Emile L., eds. (2009). Medical Physiology: A Cellular and Molecular Approach. Saunders. p. 331. ISBN 978-1-4160-3115-4.
^ Straiker, A.; Maguire, G.; Mackie, K.; Lindsey, J. (1999). "Localization of Cannabinoid CB1 Receptors in the Human Anterior Eye and Retina". Invest Ophth. Vis. Sci. 40: 2442–2448.
^ ^a ^b Pacher, P.; Mechoulam, R. (2011). "Is lipid signaling through cannabinoid 2 receptors part of a protective system?". Progress in Lipid Research. 50 (2): 193–211. PMC 3062638 . PMID 21295074. doi:10.1016/j.plipres.2011.01.001.
^ Núñez, Estefanía; Benito, Cristina; Pazos, M. Ruth; Barbachano, Antonio; Fajardo, Otto; González, Sara; Tolón, Rosa M.; Romero, Julián (2004). "Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study". Synapse. 53 (4): 208–13. PMID 15266552. doi:10.1002/syn.20050.
^ Fellermeier, Monika; Eisenreich, Wolfgang; Bacher, Adelbert; Zenk, Meinhart H. (2001). "Biosynthesis of cannabinoids". European Journal of Biochemistry. 268 (6): 1596–1604. ISSN 0014-2956. PMID 11248677. doi:10.1046/j.1432-1327.2001.02030.x.
^ Patentdocs. Patent application title: Controlled cannabis decarboxylation. US Patent application number: 20120046352. Retrieved 28 December 2013
^ ^a ^b Iseger, TA; Bossong, MG (March 2015). "A systematic review of the antipsychotic properties of cannabidiol in humans.". Schizophrenia Research. 162 (1–3): 153–61. PMID 25667194. doi:10.1016/j.schres.2015.01.033.
^ Mechoulam, Raphael; Peters, Maximilian; Murillo-Rodriguez, Eric; Hanuš, Lumír O. (2007). "Cannabidiol – Recent Advances". Chemistry & Biodiversity. 4 (8): 1678–92. PMID 17712814. doi:10.1002/cbdv.200790147.
^ Ryberg, E; Larsson, N; Sjögren, S; Hjorth, S; Hermansson, N-O; Leonova, J; Elebring, T; Nilsson, K; Drmota, T; Greasley, P J (2009). "The orphan receptor GPR55 is a novel cannabinoid receptor". British Journal of Pharmacology. 152 (7): 1092–101. PMC 2095107 . PMID 17876302. doi:10.1038/sj.bjp.0707460.
^ Russo, Ethan B.; Burnett, Andrea; Hall, Brian; Parker, Keith K. (2005). "Agonistic Properties of Cannabidiol at 5-HT1a Receptors". Neurochemical Research. 30 (8): 1037–43. PMID 16258853. doi:10.1007/s11064-005-6978-1.
^ Campos A, Moreira F, Gomes F, Del Bel EA, Guimarães F (5 December 2012). "Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders". Philos Trans R Soc Lond B Biol Sci. 367 (1607): 3364–3378. PMC 3481531 . PMID 23108553. doi:10.1098/rstb.2011.0389.
^ Frood, Arron. "Key ingredient staves off marijuana memory loss". Nature. Retrieved 6 October 2015.
^ Leweke FM, Mueller JK, Lange B, Rohleder C (2016). "Therapeutic Potential of Cannabinoids in Psychosis". Biol. Psychiatry. 79 (7): 604–12. PMID 26852073. doi:10.1016/j.biopsych.2015.11.018.
^ Mahadevan, Anu; Siegel, Craig; Martin, Billy R.; Abood, Mary E.; Beletskaya, Irina; Razdan, Raj K. (2000). "Novel Cannabinol Probes for CB1 and CB2 Cannabinoid Receptors". Journal of Medicinal Chemistry. 43 (20): 3778–85. PMID 11020293. doi:10.1021/jm0001572.
^ Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, De Petrocellis L, Buono L, Orlando P, Izzo AA (2014). "Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid". Carcinogenesis. 35 (12): 2787–97. PMID 25269802. doi:10.1093/carcin/bgu205.
^ ^a ^b Cascio, MG; Gauson, LA; Stevenson, LA; Ross, RA; Pertwee, RG (2010). "Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist". British Journal of Pharmacology. 159 (1): 129–41. PMC 2823359 . PMID 20002104. doi:10.1111/j.1476-5381.2009.00515.x.
^ Baker, PB; Gough, TA; Taylor, BJ (1980). "Illicitly imported Cannabis products: Some physical and chemical features indicative of their origin". Bulletin on narcotics. 32 (2): 31–40. PMID 6907024.
^ ^a ^b Hillig, K. W.; Mahlberg, P. G. (2004). "A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae)". American Journal of Botany. 91 (6): 966–75. PMID 21653452. doi:10.3732/ajb.91.6.966.
^ Thomas, Adèle; Stevenson, Lesley A; Wease, Kerrie N; Price, Martin R; Baillie, Gemma; Ross, Ruth A; Pertwee, Roger G (2005). "Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1and CB2receptor antagonist". British Journal of Pharmacology. 146 (7): 917–26. PMC 1751228 . PMID 16205722. doi:10.1038/sj.bjp.0706414.
^ Merkus, Frans W. H. M. (1971). "Cannabivarin and Tetrahydrocannabivarin, Two New Constituents of Hashish". Nature. 232 (5312): 579–80. PMID 4937510. doi:10.1038/232579a0.
^ Ilan, A. B.; Gevins, A.; Coleman, M.; Elsohly, M. A.; De Wit, H. (2005). "Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids". Behavioural Pharmacology. 16 (5–6): 487–96. PMID 16148455. doi:10.1097/00008877-200509000-00023.
^ "Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma | Journal of Pharmacology and Experimental Therapeutics". Jpet.aspetjournals.org. 2006-09-01. Retrieved 2017-01-03.
^ ^a ^b Bauer, Rudolf; Salo-Ahen, Karin; Bauer, Outi (2008). "CB Receptor Ligands from Plants". Current Topics in Medicinal Chemistry. 8 (3): 173–86. PMID 18289087. doi:10.2174/156802608783498023.
^ Bauer, R.; Remiger, P. (2007). "TLC and HPLC Analysis of Alkamides in Echinacea Drugs1,2". Planta Medica. 55 (4): 367–71. PMID 17262436. doi:10.1055/s-2006-962030.
^ Raduner, S; Majewska, A; Chen, J; Xie, X; Hamon, J; Faller, B; Altmann, K; Gertsch, J (2006). "Alkylamides from Echinacea Are a New Class of Cannabinomimetics: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND -INDEPENDENT IMMUNOMODULATORY EFFECTS" (PDF). J. Biol. Chem. 281 (20): 14192–14206. PMID 16547349. doi:10.1074/jbc.M601074200.
^ Perry, Nigel; Van Klink, John; Burgess, Elaine; Parmenter, Graeme (2007). "Alkamide Levels inEchinacea purpurea: A Rapid Analytical Method Revealing Differences among Roots, Rhizomes, Stems, Leaves and Flowers". Planta Medica. 63 (1): 58–62. PMID 17252329. doi:10.1055/s-2006-957605.
^ He, X; Lin, L; Bernart, MW; Lian, L (1998). "Analysis of alkamides in roots and achenes of Echinacea purpurea by liquid chromatography–electrospray mass spectrometry". Journal of Chromatography A. 815 (2): 205–11. doi:10.1016/S0021-9673(98)00447-6.
^ Ligresti, A.; Villano, R.; Allarà, M.; Ujváry, I. N.; Di Marzo, V. (2012). "Kavalactones and the endocannabinoid system: The plant-derived yangonin is a novel CB1 receptor ligand". Pharmacological Research. 66 (2): 163–169. PMID 22525682. doi:10.1016/j.phrs.2012.04.003.
^ Korte, G.; Dreiseitel, A.; Schreier, P.; Oehme, A.; Locher, S.; Geiger, S.; Heilmann, J.; Sand, P.G. (2010). "Tea catechins' affinity for human cannabinoid receptors". Phytomedicine. 17 (1): 19–22. PMID 19897346. doi:10.1016/j.phymed.2009.10.001.
^ Gertsch, J; Leonti, M; Raduner, S; Racz, I; Chen, J; Xie, X; Altmann, K; Karsak, M; Zimmer, A (2008). "Beta-caryophyllene is a dietary terpene". PNAS. 105 (26): 9099–9104. PMC 2449371 . PMID 18574142. doi:10.1073/pnas.0803601105.
^ Pacioni, Giovanni; Rapino, Cinzia; Zarivi, Osvaldo; Falconi, Anastasia; Leonardi, Marco; Battista, Natalia; Colafarina, Sabrina; Sergi, Manuel; Bonfigli, Antonella; Miranda, Michele; Barsacchi, Daniela; Maccarrone, Mauro (2015). "Truffles contain endocannabinoid metabolic enzymes and anandamide". Phytochemistry. 110: 104–110. doi:10.1016/j.phytochem.2014.11.012.
^ ^a ^b Stout, Stephen M.; Cimino, Nina M. (2014-02-01). "Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review". Drug Metabolism Reviews. 46 (1): 86–95. ISSN 0360-2532. PMID 24160757. doi:10.3109/03602532.2013.849268.
^ Aizpurua-Olaizola, Oier; Zarandona, Iratxe; Ortiz, Laura; Navarro, Patricia; Etxebarria, Nestor; Usobiaga, Aresatz (2016-01-01). "Simultaneous quantification of major cannabinoids and metabolites in human urine and plasma by HPLC-MS/MS and enzyme-alkaline hydrolysis". Drug Testing and Analysis: n/a–n/a. ISSN 1942-7611. doi:10.1002/dta.1998.
^ Ashton CH (February 2001). "Pharmacology and effects of cannabis: a brief review". Br J Psychiatry. 178 (2): 101–106. PMID 11157422. doi:10.1192/bjp.178.2.101. Because they are extremely lipid soluble, cannabinoids accumulate in fatty tissues, reaching peak concentrations in 4-5 days. They are then slowly released back into other body compartments, including the brain. They are then slowly released back into other body compartments, including the brain. Because of the sequestration in fat, the tissue elimination half-life of THC is about 7 days, and complete elimination of a single dose may take up to 30 days.
^ Katona I, Freund TF (2012). "Multiple functions of endocannabinoid signaling in the brain". Annual Review of Neuroscience. 35: 529–58. PMC 4273654 . PMID 22524785. doi:10.1146/annurev-neuro-062111-150420.
^ ^a ^b ^c Grotenhermen, Franjo (2005). "Cannabinoids". Current Drug Target -CNS & Neurological Disorders. 4 (5): 507–530. doi:10.2174/156800705774322111.
^ Martin, B.R.; Mechoulam, R.; Razdan, R.K. (1999). "Discovery and characterization of endogenous cannabinoids". Life Sciences. 65 (6–7): 573–595. doi:10.1016/S0024-3205(99)00281-7.
^ Di Tomaso, Emmanuelle; Beltramo, Massimiliano; Piomelli, Daniele (1996). "Brain cannabinoids in chocolate". Nature. 382 (6593): 677–8. PMID 8751435. doi:10.1038/382677a0.
^ Chapman, K. D.; Venables, B; Markovic, R; Blair Jr, RW; Bettinger, C (1999). "N-Acylethanolamines in Seeds. Quantification of Molecular Species and Their Degradation upon Imbibition". Plant Physiology. 120 (4): 1157–64. PMC 59349 . PMID 10444099. doi:10.1104/pp.120.4.1157.
^ Sepe, Nunzio; De Petrocellis, Luciano; Montanaro, Francesca; Cimino, Guido; Di Marzo, Vincenzo (1998). "Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs". Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 1389 (2): 101–11. PMID 9461251. doi:10.1016/S0005-2760(97)00132-X.
^ Piomelli, Daniele; Schweitzer, Nephi; Piomelli, Paul (1997). "A second endogenous cannabinoid that modulates long-term potentiation". Nature. 388 (6644): 773–8. PMID 9285589. doi:10.1038/42015.
^ Savinainen, Juha R; Järvinen, Tomi; Laine, Krista; Laitinen, Jarmo T (2001). "Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB1receptor-dependent G-protein activation in rat cerebellar membranes". British Journal of Pharmacology. 134 (3): 664–72. PMC 1572991 . PMID 11588122. doi:10.1038/sj.bjp.0704297.
^ Hanuš, Lumír; Abu-Lafi, Saleh; Fride, Ester; Breuer, Aviva; Vogel, Zvi; Shalev, Deborah E.; Kustanovich, Irina; Mechoulam, Raphael (2001). "2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor". Proceedings of the National Academy of Sciences. 98 (7): 3662–5. PMC 31108 . PMID 11259648. doi:10.1073/pnas.061029898.
^ Oka, Saori; Tsuchie, Akiko; Tokumura, Akira; Muramatsu, Mayumi; Suhara, Yoshitomo; Takayama, Hiroaki; Waku, Keizo; Sugiura, Takayuki (2003). "Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species". Journal of Neurochemistry. 85 (6): 1374–81. PMID 12787057. doi:10.1046/j.1471-4159.2003.01804.x.
^ Bisogno, Tiziana; Melck, Dominique; Bobrov, Mikhail Yu.; Gretskaya, Natalia M.; Bezuglov, Vladimir V.; De Petrocellis, Luciano; Di Marzo, Vincenzo (2000). "N-acyl-dopamines: Novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo". Biochemical Journal. 351 (3): 817–24. PMC 1221424 . PMID 11042139. doi:10.1042/bj3510817.
^ Bisogno, T; Ligresti, A; Dimarzo, V (2005). "The endocannabinoid signalling system: Biochemical aspects". Pharmacology Biochemistry and Behavior. 81 (2): 224–38. PMID 15935454. doi:10.1016/j.pbb.2005.01.027.
^ Ralevic, Vera (2003). "Cannabinoid modulation of peripheral autonomic and sensory neurotransmission". European Journal of Pharmacology. 472 (1–2): 1–21. PMID 12860468. doi:10.1016/S0014-2999(03)01813-2.
^ Porter, A. C.; Sauer, JM; Knierman, MD; Becker, GW; Berna, MJ; Bao, J; Nomikos, GG; Carter, P; Bymaster, FP; Leese, AB; Felder, CC (2002). "Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor". Journal of Pharmacology and Experimental Therapeutics. 301 (3): 1020–4. PMID 12023533. doi:10.1124/jpet.301.3.1020.
^ Piñeiro, Roberto; Falasca, Marco (2012). "Lysophosphatidylinositol signalling: New wine from an old bottle". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1821 (4): 694–705. PMID 22285325. doi:10.1016/j.bbalip.2012.01.009.
^ Fride, E; Bregman, T; Kirkham, TC (2005). "Endocannabinoids and food intake: Newborn suckling and appetite regulation in adulthood". Experimental biology and medicine. 230 (4): 225–34. PMID 15792943.
^ ElSohly, Mahmoud A.; Gul, Waseem; Wanas, Amira S.; Radwan, Mohamed M. (2014-02-27). "Synthetic cannabinoids: Analysis and metabolites". Life Sciences. Special Issue: Emerging Trends in the Abuse of Designer Drugs and Their Catastrophic Health Effects: Update on Chemistry, Pharmacology, Toxicology and Addiction Potential. 97 (1): 78–90. doi:10.1016/j.lfs.2013.12.212.
^ Lauritsen, Kirstin J.; Rosenberg, Harold (2016-02-24). "Comparison of outcome expectancies for synthetic cannabinoids and botanical marijuana". The American Journal of Drug and Alcohol Abuse. 42 (4): 377–84. ISSN 0095-2990. PMID 26910181. doi:10.3109/00952990.2015.1135158.
^ ^a ^b "N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide(AB-CHMINACA), N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA)and[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone(THJ-2201)" (PDF). Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration. December 2014.
^ "More medicinal uses for marijuana". Marijuana.org. October 18, 2005. Archived from the original on 2005-12-21. Retrieved 2014-01-15.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 合成カンナビノイド：急性中毒 synthetic cannabinoids acute intoxication
2. 大麻（マリファナ）：急性中毒 cannabis marijuana acute intoxication
3. 大麻使用障害：治療、予後、および長期的な効果 cannabis use disorder treatment prognosis and long term medical effects
4. 癌疼痛のマネージメント：鎮痛補助剤（鎮痛剤） cancer pain management adjuvant analgesics coanalgesics
5. 緩和ケアの最新情報 whats new in palliative care

English Journal

Cannabis use and bone mineral density: NHANES 2007-2010.

Bourne D1, Plinke W1, Hooker ER1, Nielson CM2.
Archives of osteoporosis.Arch Osteoporos.2017 Dec;12(1):29. doi: 10.1007/s11657-017-0320-9. Epub 2017 Mar 13.
PMID 28286929

Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors.

Mollica A1, Pelliccia S2, Famiglini V2, Stefanucci A1, Macedonio G1, Chiavaroli A1, Orlando G1, Brunetti L1, Ferrante C1, Pieretti S3, Novellino E4, Benyhe S5, Zador F5, Erdei A5, Szucs E5, Samavati R5, Dvrorasko S5, Tomboly C5, Ragno R6,7, Patsilinakos A6,7, Silvestri R2.
Journal of enzyme inhibition and medicinal chemistry.J Enzyme Inhib Med Chem.2017 Dec;32(1):444-451. doi: 10.1080/14756366.2016.1260565.
PMID 28097916

Analysis of cannabinoids by liquid chromatography-mass spectrometry in milk, liver and hemp seed to ensure food safety.

Escrivá Ú1, Andrés-Costa MJ2, Andreu V3, Picó Y1.
Food chemistry.Food Chem.2017 Aug 1;228:177-185. doi: 10.1016/j.foodchem.2017.01.128. Epub 2017 Jan 28.
PMID 28317711

Japanese Journal

薬物簡易スクリーニングキットを用いた危険ドラッグ成分である合成カンナビノイドの識別法の検討

内山奈穂子,花尻(木倉) 瑠理,袴塚高志
薬学雑誌 135(3), 535-541, 2015
NAID 40020380393

薬物簡易スクリーニングキットを用いた危険ドラッグ成分である合成カンナビノイドの識別法の検討

内山奈穂子,花尻(木倉) 瑠理,袴塚高志
薬学雑誌. 乙号 advpub(0), 2015
… In this study, we evaluated the on-site drug-testing device ``K2/Spice Test for the detection of 12 different types of 38 synthetic cannabinoids (including 13 naphthoylindole-type synthetic cannabinoids) and a natural cannabinoid (Δ9-tetrahydrocannabinol). …
NAID 130004756531

薬物簡易スクリーニングキットを用いた危険ドラッグ成分である合成カンナビノイドの識別法の検討

内山奈穂子,花尻（木倉）瑠理,袴塚高志
薬学雑誌. 乙号 135(3), 535-541, 2015
… In this study, we evaluated the on-site drug-testing device "K2/Spice Test" for the detection of 12 different types of 38 synthetic cannabinoids (including 13 naphthoylindole-type synthetic cannabinoids) and a natural cannabinoid (Δ9-tetrahydrocannabinol). …
NAID 130004756504

Related Pictures

★リンクテーブル★

リンク元	「カンナビノイド」
拡張検索	「endocannabinoid」「endogenous cannabinoid」

「カンナビノイド」

　　[★]

英: cannabinoid, cannabinoids
関: 大麻類、大麻

マリファナなどの作用に関係する化学物質

「endocannabinoid」

　　[★]

内在性カンナビノイド、エンドカンナビノイド

関: endogenous cannabinoid

「endogenous cannabinoid」

　　[★]

内在性カンナビノイド、内因性カンナビノイド

関: endocannabinoid

[pmid16968947-1] Pacher, P.; Bátkai, S; Kunos, G (2006). "The Endocannabinoid System as an Emerging Target of Pharmacotherapy". Pharmacological Reviews. 58 (3): 389–462. PMC 2241751 . PMID 16968947. doi:10.1124/pr.58.3.2.

[lambert-2] Lambert, Didier M.; Fowler, Christopher J. (2005). "The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications". Journal of Medicinal Chemistry. 48 (16): 5059–87. PMID 16078824. doi:10.1021/jm058183t.

[3] Pertwee, Roger, ed. (2005). Cannabinoids. Springer-Verlag. p. 2. ISBN 3-540-22565-X.

[4] "Bulletin on Narcotics – 1962 Issue 3 – 004". UNODC (United Nations Office of Drugs and Crime). 1962-01-01. Retrieved 2014-01-15.

[:0-5] Aizpurua-Olaizola, Oier; Soydaner, Umut; Öztürk, Ekin; Schibano, Daniele; Simsir, Yilmaz; Navarro, Patricia; Etxebarria, Nestor; Usobiaga, Aresatz (2016-02-02). "Evolution of the Cannabinoid and Terpene Content during the Growth ofCannabis sativaPlants from Different Chemotypes". Journal of Natural Products. 79 (2): 324–331. PMID 26836472. doi:10.1021/acs.jnatprod.5b00949.

[pmid2848184-6] Devane, WA; Dysarz, FA 3rd; Johnson, MR; Melvin, LS; Howlett, AC (1988). "Determination and characterization of a cannabinoid receptor in rat brain". Mol Pharmacol. 34 (5): 605–13. PMID 2848184. Retrieved 6 June 2015.

[pmid15866316-7] Begg, Malcolm; Pacher, Pál; Batkai, Sándor; Oseihyiaman, Douglas; Offertaler, László; Mo, Fong Ming; Liu, Jie; Kunos, George (2005). "Evidence for novel cannabinoid receptors". Pharmacology & Therapeutics. 106 (2): 133–45. PMID 15866316. doi:10.1016/j.pharmthera.2004.11.005.

[Medical_Physiology-8] Boron, Walter F.; Boulpaep, Emile L., eds. (2009). Medical Physiology: A Cellular and Molecular Approach. Saunders. p. 331. ISBN 978-1-4160-3115-4.

[9] Straiker, A.; Maguire, G.; Mackie, K.; Lindsey, J. (1999). "Localization of Cannabinoid CB1 Receptors in the Human Anterior Eye and Retina". Invest Ophth. Vis. Sci. 40: 2442–2448.

[pmid21295074-10] Pacher, P.; Mechoulam, R. (2011). "Is lipid signaling through cannabinoid 2 receptors part of a protective system?". Progress in Lipid Research. 50 (2): 193–211. PMC 3062638 . PMID 21295074. doi:10.1016/j.plipres.2011.01.001.

[pmid15266552-11] Núñez, Estefanía; Benito, Cristina; Pazos, M. Ruth; Barbachano, Antonio; Fajardo, Otto; González, Sara; Tolón, Rosa M.; Romero, Julián (2004). "Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study". Synapse. 53 (4): 208–13. PMID 15266552. doi:10.1002/syn.20050.

[FellermeierEisenreich2001-12] Fellermeier, Monika; Eisenreich, Wolfgang; Bacher, Adelbert; Zenk, Meinhart H. (2001). "Biosynthesis of cannabinoids". European Journal of Biochemistry. 268 (6): 1596–1604. ISSN 0014-2956. PMID 11248677. doi:10.1046/j.1432-1327.2001.02030.x.

[13] Patentdocs. Patent application title: Controlled cannabis decarboxylation. US Patent application number: 20120046352. Retrieved 28 December 2013

[2015CBDantipsychReview-14] Iseger, TA; Bossong, MG (March 2015). "A systematic review of the antipsychotic properties of cannabidiol in humans.". Schizophrenia Research. 162 (1–3): 153–61. PMID 25667194. doi:10.1016/j.schres.2015.01.033.

[recentadvances-15] Mechoulam, Raphael; Peters, Maximilian; Murillo-Rodriguez, Eric; Hanuš, Lumír O. (2007). "Cannabidiol – Recent Advances". Chemistry & Biodiversity. 4 (8): 1678–92. PMID 17712814. doi:10.1002/cbdv.200790147.

[16] Ryberg, E; Larsson, N; Sjögren, S; Hjorth, S; Hermansson, N-O; Leonova, J; Elebring, T; Nilsson, K; Drmota, T; Greasley, P J (2009). "The orphan receptor GPR55 is a novel cannabinoid receptor". British Journal of Pharmacology. 152 (7): 1092–101. PMC 2095107 . PMID 17876302. doi:10.1038/sj.bjp.0707460.

[pmid16258853-17] Russo, Ethan B.; Burnett, Andrea; Hall, Brian; Parker, Keith K. (2005). "Agonistic Properties of Cannabidiol at 5-HT1a Receptors". Neurochemical Research. 30 (8): 1037–43. PMID 16258853. doi:10.1007/s11064-005-6978-1.

[18] Campos A, Moreira F, Gomes F, Del Bel EA, Guimarães F (5 December 2012). "Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders". Philos Trans R Soc Lond B Biol Sci. 367 (1607): 3364–3378. PMC 3481531 . PMID 23108553. doi:10.1098/rstb.2011.0389.

[NatureCBDMemory-19] Frood, Arron. "Key ingredient staves off marijuana memory loss". Nature. Retrieved 6 October 2015.

[20] Leweke FM, Mueller JK, Lange B, Rohleder C (2016). "Therapeutic Potential of Cannabinoids in Psychosis". Biol. Psychiatry. 79 (7): 604–12. PMID 26852073. doi:10.1016/j.biopsych.2015.11.018.

[pmid11020293-21] Mahadevan, Anu; Siegel, Craig; Martin, Billy R.; Abood, Mary E.; Beletskaya, Irina; Razdan, Raj K. (2000). "Novel Cannabinol Probes for CB1 and CB2 Cannabinoid Receptors". Journal of Medicinal Chemistry. 43 (20): 3778–85. PMID 11020293. doi:10.1021/jm0001572.

[22] Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, De Petrocellis L, Buono L, Orlando P, Izzo AA (2014). "Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid". Carcinogenesis. 35 (12): 2787–97. PMID 25269802. doi:10.1093/carcin/bgu205.

[pmid20002104-23] Cascio, MG; Gauson, LA; Stevenson, LA; Ross, RA; Pertwee, RG (2010). "Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist". British Journal of Pharmacology. 159 (1): 129–41. PMC 2823359 . PMID 20002104. doi:10.1111/j.1476-5381.2009.00515.x.

[24] Baker, PB; Gough, TA; Taylor, BJ (1980). "Illicitly imported Cannabis products: Some physical and chemical features indicative of their origin". Bulletin on narcotics. 32 (2): 31–40. PMID 6907024.

[HilligMahlberg-25] Hillig, K. W.; Mahlberg, P. G. (2004). "A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae)". American Journal of Botany. 91 (6): 966–75. PMID 21653452. doi:10.3732/ajb.91.6.966.

[26] Thomas, Adèle; Stevenson, Lesley A; Wease, Kerrie N; Price, Martin R; Baillie, Gemma; Ross, Ruth A; Pertwee, Roger G (2005). "Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1and CB2receptor antagonist". British Journal of Pharmacology. 146 (7): 917–26. PMC 1751228 . PMID 16205722. doi:10.1038/sj.bjp.0706414.

[27] Merkus, Frans W. H. M. (1971). "Cannabivarin and Tetrahydrocannabivarin, Two New Constituents of Hashish". Nature. 232 (5312): 579–80. PMID 4937510. doi:10.1038/232579a0.

[behaviouralpharm-28] Ilan, A. B.; Gevins, A.; Coleman, M.; Elsohly, M. A.; De Wit, H. (2005). "Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids". Behavioural Pharmacology. 16 (5–6): 487–96. PMID 16148455. doi:10.1097/00008877-200509000-00023.

[29] "Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma | Journal of Pharmacology and Experimental Therapeutics". Jpet.aspetjournals.org. 2006-09-01. Retrieved 2017-01-03.

[Woelkart-2008-30] Bauer, Rudolf; Salo-Ahen, Karin; Bauer, Outi (2008). "CB Receptor Ligands from Plants". Current Topics in Medicinal Chemistry. 8 (3): 173–86. PMID 18289087. doi:10.2174/156802608783498023.

[Bauer-1989-31] Bauer, R.; Remiger, P. (2007). "TLC and HPLC Analysis of Alkamides in Echinacea Drugs1,2". Planta Medica. 55 (4): 367–71. PMID 17262436. doi:10.1055/s-2006-962030.

[32] Raduner, S; Majewska, A; Chen, J; Xie, X; Hamon, J; Faller, B; Altmann, K; Gertsch, J (2006). "Alkylamides from Echinacea Are a New Class of Cannabinomimetics: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND -INDEPENDENT IMMUNOMODULATORY EFFECTS" (PDF). J. Biol. Chem. 281 (20): 14192–14206. PMID 16547349. doi:10.1074/jbc.M601074200.

[Perry-1997-33] Perry, Nigel; Van Klink, John; Burgess, Elaine; Parmenter, Graeme (2007). "Alkamide Levels inEchinacea purpurea: A Rapid Analytical Method Revealing Differences among Roots, Rhizomes, Stems, Leaves and Flowers". Planta Medica. 63 (1): 58–62. PMID 17252329. doi:10.1055/s-2006-957605.

[34] He, X; Lin, L; Bernart, MW; Lian, L (1998). "Analysis of alkamides in roots and achenes of Echinacea purpurea by liquid chromatography–electrospray mass spectrometry". Journal of Chromatography A. 815 (2): 205–11. doi:10.1016/S0021-9673(98)00447-6.

[35] Ligresti, A.; Villano, R.; Allarà, M.; Ujváry, I. N.; Di Marzo, V. (2012). "Kavalactones and the endocannabinoid system: The plant-derived yangonin is a novel CB1 receptor ligand". Pharmacological Research. 66 (2): 163–169. PMID 22525682. doi:10.1016/j.phrs.2012.04.003.

[urlmissclasses.com-36] Korte, G.; Dreiseitel, A.; Schreier, P.; Oehme, A.; Locher, S.; Geiger, S.; Heilmann, J.; Sand, P.G. (2010). "Tea catechins' affinity for human cannabinoid receptors". Phytomedicine. 17 (1): 19–22. PMID 19897346. doi:10.1016/j.phymed.2009.10.001.

[37] Gertsch, J; Leonti, M; Raduner, S; Racz, I; Chen, J; Xie, X; Altmann, K; Karsak, M; Zimmer, A (2008). "Beta-caryophyllene is a dietary terpene". PNAS. 105 (26): 9099–9104. PMC 2449371 . PMID 18574142. doi:10.1073/pnas.0803601105.

[38] Pacioni, Giovanni; Rapino, Cinzia; Zarivi, Osvaldo; Falconi, Anastasia; Leonardi, Marco; Battista, Natalia; Colafarina, Sabrina; Sergi, Manuel; Bonfigli, Antonella; Miranda, Michele; Barsacchi, Daniela; Maccarrone, Mauro (2015). "Truffles contain endocannabinoid metabolic enzymes and anandamide". Phytochemistry. 110: 104–110. doi:10.1016/j.phytochem.2014.11.012.

[:1-39] Stout, Stephen M.; Cimino, Nina M. (2014-02-01). "Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review". Drug Metabolism Reviews. 46 (1): 86–95. ISSN 0360-2532. PMID 24160757. doi:10.3109/03602532.2013.849268.

[40] Aizpurua-Olaizola, Oier; Zarandona, Iratxe; Ortiz, Laura; Navarro, Patricia; Etxebarria, Nestor; Usobiaga, Aresatz (2016-01-01). "Simultaneous quantification of major cannabinoids and metabolites in human urine and plasma by HPLC-MS/MS and enzyme-alkaline hydrolysis". Drug Testing and Analysis: n/a–n/a. ISSN 1942-7611. doi:10.1002/dta.1998.

[41] Ashton CH (February 2001). "Pharmacology and effects of cannabis: a brief review". Br J Psychiatry. 178 (2): 101–106. PMID 11157422. doi:10.1192/bjp.178.2.101. Because they are extremely lipid soluble, cannabinoids accumulate in fatty tissues, reaching peak concentrations in 4-5 days. They are then slowly released back into other body compartments, including the brain. They are then slowly released back into other body compartments, including the brain. Because of the sequestration in fat, the tissue elimination half-life of THC is about 7 days, and complete elimination of a single dose may take up to 30 days.

[42] Katona I, Freund TF (2012). "Multiple functions of endocannabinoid signaling in the brain". Annual Review of Neuroscience. 35: 529–58. PMC 4273654 . PMID 22524785. doi:10.1146/annurev-neuro-062111-150420.

[grotenhermen_2005-43] Grotenhermen, Franjo (2005). "Cannabinoids". Current Drug Target -CNS & Neurological Disorders. 4 (5): 507–530. doi:10.2174/156800705774322111.

[pmid10462059-44] Martin, B.R.; Mechoulam, R.; Razdan, R.K. (1999). "Discovery and characterization of endogenous cannabinoids". Life Sciences. 65 (6–7): 573–595. doi:10.1016/S0024-3205(99)00281-7.

[pmid8751435-45] Di Tomaso, Emmanuelle; Beltramo, Massimiliano; Piomelli, Daniele (1996). "Brain cannabinoids in chocolate". Nature. 382 (6593): 677–8. PMID 8751435. doi:10.1038/382677a0.

[46] Chapman, K. D.; Venables, B; Markovic, R; Blair Jr, RW; Bettinger, C (1999). "N-Acylethanolamines in Seeds. Quantification of Molecular Species and Their Degradation upon Imbibition". Plant Physiology. 120 (4): 1157–64. PMC 59349 . PMID 10444099. doi:10.1104/pp.120.4.1157.

[47] Sepe, Nunzio; De Petrocellis, Luciano; Montanaro, Francesca; Cimino, Guido; Di Marzo, Vincenzo (1998). "Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs". Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 1389 (2): 101–11. PMID 9461251. doi:10.1016/S0005-2760(97)00132-X.

[stella_1997-48] Piomelli, Daniele; Schweitzer, Nephi; Piomelli, Paul (1997). "A second endogenous cannabinoid that modulates long-term potentiation". Nature. 388 (6644): 773–8. PMID 9285589. doi:10.1038/42015.

[49] Savinainen, Juha R; Järvinen, Tomi; Laine, Krista; Laitinen, Jarmo T (2001). "Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB1receptor-dependent G-protein activation in rat cerebellar membranes". British Journal of Pharmacology. 134 (3): 664–72. PMC 1572991 . PMID 11588122. doi:10.1038/sj.bjp.0704297.

[50] Hanuš, Lumír; Abu-Lafi, Saleh; Fride, Ester; Breuer, Aviva; Vogel, Zvi; Shalev, Deborah E.; Kustanovich, Irina; Mechoulam, Raphael (2001). "2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor". Proceedings of the National Academy of Sciences. 98 (7): 3662–5. PMC 31108 . PMID 11259648. doi:10.1073/pnas.061029898.

[Oka_2003-51] Oka, Saori; Tsuchie, Akiko; Tokumura, Akira; Muramatsu, Mayumi; Suhara, Yoshitomo; Takayama, Hiroaki; Waku, Keizo; Sugiura, Takayuki (2003). "Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species". Journal of Neurochemistry. 85 (6): 1374–81. PMID 12787057. doi:10.1046/j.1471-4159.2003.01804.x.

[52] Bisogno, Tiziana; Melck, Dominique; Bobrov, Mikhail Yu.; Gretskaya, Natalia M.; Bezuglov, Vladimir V.; De Petrocellis, Luciano; Di Marzo, Vincenzo (2000). "N-acyl-dopamines: Novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo". Biochemical Journal. 351 (3): 817–24. PMC 1221424 . PMID 11042139. doi:10.1042/bj3510817.

[Bisogno_2005-53] Bisogno, T; Ligresti, A; Dimarzo, V (2005). "The endocannabinoid signalling system: Biochemical aspects". Pharmacology Biochemistry and Behavior. 81 (2): 224–38. PMID 15935454. doi:10.1016/j.pbb.2005.01.027.

[54] Ralevic, Vera (2003). "Cannabinoid modulation of peripheral autonomic and sensory neurotransmission". European Journal of Pharmacology. 472 (1–2): 1–21. PMID 12860468. doi:10.1016/S0014-2999(03)01813-2.

[55] Porter, A. C.; Sauer, JM; Knierman, MD; Becker, GW; Berna, MJ; Bao, J; Nomikos, GG; Carter, P; Bymaster, FP; Leese, AB; Felder, CC (2002). "Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor". Journal of Pharmacology and Experimental Therapeutics. 301 (3): 1020–4. PMID 12023533. doi:10.1124/jpet.301.3.1020.

[56] Piñeiro, Roberto; Falasca, Marco (2012). "Lysophosphatidylinositol signalling: New wine from an old bottle". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1821 (4): 694–705. PMID 22285325. doi:10.1016/j.bbalip.2012.01.009.

[57] Fride, E; Bregman, T; Kirkham, TC (2005). "Endocannabinoids and food intake: Newborn suckling and appetite regulation in adulthood". Experimental biology and medicine. 230 (4): 225–34. PMID 15792943.

[58] ElSohly, Mahmoud A.; Gul, Waseem; Wanas, Amira S.; Radwan, Mohamed M. (2014-02-27). "Synthetic cannabinoids: Analysis and metabolites". Life Sciences. Special Issue: Emerging Trends in the Abuse of Designer Drugs and Their Catastrophic Health Effects: Update on Chemistry, Pharmacology, Toxicology and Addiction Potential. 97 (1): 78–90. doi:10.1016/j.lfs.2013.12.212.

[59] Lauritsen, Kirstin J.; Rosenberg, Harold (2016-02-24). "Comparison of outcome expectancies for synthetic cannabinoids and botanical marijuana". The American Journal of Drug and Alcohol Abuse. 42 (4): 377–84. ISSN 0095-2990. PMID 26910181. doi:10.3109/00952990.2015.1135158.

[DCES-60] "N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide(AB-CHMINACA), N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA)and[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone(THJ-2201)" (PDF). Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration. December 2014.

[61] "More medicinal uses for marijuana". Marijuana.org. October 18, 2005. Archived from the original on 2005-12-21. Retrieved 2014-01-15.

Cannabis
Part of a series on

Arts Culture 420 Counterculture of the 1960s Entheogenic use of cannabis Hippie Magu (deity) Rastafari Stoner film Stoner rock
Chemistry Cannabinoid receptors Cannabinoid receptor type 1 Cannabinoid receptor type 2 Cannabinoids 2-AG 2-AGE, Noladin ether AEA CBC CBL CBD CBDV CBG CBN CBV NADA THC THCV Virodhamine Synthetic cannabinoids AM-2201 CP-55940 Dimethylheptylpyran HU-210 HU-331 JWH-018 JWH-073 JWH-133 Levonantradol SR144528 WIN 55,212-2
Consumption Blunt Bong Cannabis smoking Gravity bong Joint Roach Vaporizer
Economics Cannabis coffee shop Cannabis cultivation Cannabis dispensary Cannabis Social Club Grow house Grow shop Head shop Marijuana vending machine
Effects Dependence Drug testing Effects of legalized cannabis Gateway drug theory Long term effects Medicine Memory Pregnancy Psychosis Time perception
Forms Bhang Charas Edibles Flower essential oil Hash oil Hashish Hemp Hemp oil Kief Synthetic cannabis Thai stick Tea Tincture
Law Cannabis political parties Decriminalizing Cannabis in the US Drug policy of California Drug policy of Colorado Drug policy of Portugal Drug policy of the Netherlands Legal and medical status of cannabis Legal history of cannabis in the US Legality of cannabis Legality of cannabis by country Legality of cannabis in the US Legal history of cannabis in Canada Timeline of cannabis US Legalization Timeline
Regional Adult lifetime cannabis use by country Annual cannabis use by country Afghanistan Alabama American Samoa Arkansas Australia British Columbia California Chile Egypt Georgia (USA) Guam Idaho India Indiana Iowa Jamaica Kansas Kentucky Louisiana Maine Massachusetts Montana Morocco Nebraska New Zealand Nigeria North Dakota North Mariana Islands Oregon Palau Papua New Guinea Paraguay Portugal South Dakota Svalbard Switzerland Tennessee U.K. U.S. Uruguay Utah Vermont Virginia Virginia Wisconsin Wyoming American Indian reservations Marijuana tourism in the U.S.
Variants Autoflowering cannabis Cannabis genus Cannabis indica Cannabis ruderalis Cannabis sativa Cannabis strains Acapulco Gold Blue Dream Charlotte's web Kush Malawi Gold Sour Diesel
Related Drug culture Illegal drug trade Psychedelia
Cannabis portal Medicine portal
v t e

匿名

検索

案内

cannabinoid